Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study

被引:7
作者
Xu, Junhui [1 ]
Wang, Mangju [1 ]
Shen, Ye [1 ]
Yan, Miao [1 ]
Xie, Weiwei [1 ]
Wang, Bingjie [1 ]
Liu, Huihui [1 ]
Cen, Xinan [1 ]
机构
[1] Peking Univ First Hosp, Dept Hematol, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
symptomatic multiple myeloma; smoldering multiple myeloma; AL amyloidosis; poor prognostic factor; AL AMYLOIDOSIS; STAGING SYSTEM; DIAGNOSIS; CRITERIA;
D O I
10.2147/CMAR.S287922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Amyloid light-chain amyloidosis (AL amyloidosis) is commonly associated with multiple myeloma. However, the clinical characteristics and prognosis of symptomatic and smoldering multiple myeloma with AL amyloidosis are not particularly clear. Methods: Patients with symptomatic and smoldering multiple myeloma in the Peking University First Hospital registry from 2010 to 2018 were studied. The clinical and laboratory information was collected from first presentation to death or until the last available clinical follow-up. The patients' survival and outcomes were analyzed, and the relationship between the clinical parameters and survival was also assessed. Results: Compared with symptomatic multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP >= 700pg/mL (P<0.001), ALP>187.5IU/L (P=0.032) and ALB<25g/L (P<0.001). Similarly, compared with smoldering multiple myeloma patients without AL amyloidosis, patients with AL amyloidosis had higher incidence of BNP >= 700pg/mL (P=0.030) and Alb<25g/L (P=0.024). The existence of AL amyloidosis, especially those with the heart involvement, was related to shorter long-term survival of symptomatic and smoldering multiple myeloma according to univariate analyses. Renal involvement and gastrointestinal tract involvement had an impact on the prognosis of smoldering multiple myeloma but not on the symptomatic multiple myeloma. Cox regression model for overall survival detected BNP >= 700pg/mL in symptomatic multiple myeloma having independent poorer prognostic significance (HR=2.455, P=0.004). Interestingly, BNP at diagnosis was significantly correlated with cardiac amyloidosis (r=0.496, P<0.001). Cox regression model for overall survival detected the presence of AL amyloidosis in smoldering multiple myeloma having independent poorer prognostic significance (HR=8.741, P=0.002). Conclusion: AL amyloidosis is an independent poor prognostic factor for not only symptomatic multiple myeloma but also smoldering multiple myeloma. It is mainly because of involvement of important organs, especially the heart. AL amyloidosis probably has a greater impact on the prognosis of smoldering multiple myeloma than on the symptomatic multiple myeloma.
引用
收藏
页码:1343 / 1356
页数:14
相关论文
共 50 条
  • [21] Multiple Myeloma Associated with Light-Chain Amyloidosis Manifesting as Gastric Retention: A Case Report and Review of the Literature
    Liu, W.
    Zhou, X.
    WEST INDIAN MEDICAL JOURNAL, 2011, 60 (06) : 681 - 684
  • [22] Cyclophosphamide plus Thalidomide plus Dexamethasone Versus Melphalan plus Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients
    Liu, Baojian
    Wang, Yan
    Bai, Ming
    Wang, Di
    Zhao, Jin
    Zhang, Ming
    Sun, Shiren
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1186 - 1198
  • [23] The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma
    He, Haiyan
    Lu, Jing
    Qiang, Wanting
    Liu, Jin
    Liang, Aibin
    Du, Juan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [24] 'Transformation' from amyloid light chain amyloidosis to symptomatic multiple myeloma
    Rutten, K. H. G.
    Raymakers, R. A. P.
    Minnema, M. C.
    NETHERLANDS JOURNAL OF MEDICINE, 2018, 76 (05) : 249 - 250
  • [25] Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis
    Usnarska-Zubkiewicz, Lidia
    Holojda, Jadwiga
    Debski, Jakub
    Zubkiewicz-Zarebska, Anna
    Zagocka, Ewa
    Kuliczkowski, Kazimierz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (04): : 531 - 538
  • [26] The Occurrence of AL Amyloidosis (Light-Chain Amyloidosis) in Patients with Multiple Myeloma in Lower Silesia Region, Poland
    Usnarska-Zubkiewicz, Lidia
    Holojda, Jadwiga
    Jelen, Michal
    Zubkiewicz-Zarebska, Anna
    Debski, Jakub
    Kuliczkowski, Kazimierz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (02): : 235 - 244
  • [27] Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience
    Jimenez-Zepeda, Victor H.
    Duggan, Peter
    Neri, Paola
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06) : E79 - E84
  • [28] Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China
    Li, Sheng
    He, Weiting
    Yau, Hok-him
    Xie, Jianteng
    Zhu, Yaxi
    Chen, Xiaojie
    Zhang, Shaogui
    Zhang, Yifan
    Liao, Pengjun
    Liu, Hui
    Li, Liwen
    Zhong, Liye
    Wang, Wenjian
    RENAL FAILURE, 2025, 47 (01)
  • [29] Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study
    Kumar, Shaji
    Dispenzieri, Angela
    Bhutani, Divaya
    Gertz, Morie
    Wechalekar, Ashutosh
    Palladini, Giovanni
    Comenzo, Raymond
    Fonseca, Rafael
    Jaccard, Arnaud
    Kastritis, Efstathios
    Schoenland, Stefan
    la Porte, Charles
    Pei, Huiling
    Tran, NamPhuong
    Merlini, Giampaolo
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (03): : 268 - 278
  • [30] Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis
    Yu, Yuanyuan
    Huang, Zhongxia
    Hu, Wanli
    Li, Xin
    Shen, Man
    Zhang, Jiajia
    Tang, Ran
    Chen, Shilun
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (08) : 519 - +